Short-term amiodarone therapy after reversion of persistent atrial fibrillation reduces recurrences at 18 months

• Published in: Cardiology journal Vol. 21; no. 4; pp. 397 - 404
• Main Authors: Galperin, Jorge, Elizari, Marcelo V, Bonato, Ricardo, Ledesma, Raul, Vazquez Blanco, Manuel, Lago, Manuel, Spada, Pablo, Sanchez, Jorge, Piasentin, Jorge, Chiale, Pablo A
• Format: Journal Article
• Language: English
• Published: Poland Wydawnictwo Via Medica 01.01.2014
• Subjects: Aged; Aged, 80 and over; Amiodarone - administration & dosage; Anti-Arrhythmia Agents - administration & dosage; Argentina; Atrial Fibrillation - diagnosis; Atrial Fibrillation - physiopathology; Atrial Fibrillation - therapy; Bayes Theorem; Cardiac arrhythmia; Combined Modality Therapy; Disease-Free Survival; Double-Blind Method; Drug Administration Schedule; Echocardiography, Doppler; Electric Countershock - adverse effects; Electrocardiography, Ambulatory; Female; Heart Conduction System - drug effects; Heart Conduction System - physiopathology; Heart Rate - drug effects; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Recurrence; Sinuses; Time Factors; Treatment Outcome; Argentina
• ISSN: 1897-5593; 1897-5593; 1898-018X
• DOI: 10.5603/CJ.a2013.0152

The aim of this study was to compare the outcome of 3 months vs. 18 months of amiodarone treatment after atrial fibrillation (AF) conversion in patients who experienced the first episode of persistent AF. We included 51 patients who experienced the first episode of persistent AF receiving amiodarone (600 mg) daily for 4-6 weeks. If AF persisted, electrical cardioversion (ECV) was performed. All patients received amiodarone (200 mg daily) for 3 months and then were randomized to amiodarone (Group I) or placebo (Group II) and followed for 15 months. The control group comprised 9 untreated patients undergoing ECV. Treatment effectiveness was evaluated using a Bayesian model. Eighteen months after AF reversion, 22 (81.5%) patients in Group I, 13 (54.2%) patients in Group II, and 1 (11.1%) patient in the control group remained in sinus rhythm. No differences were found between Group I patients who required ECV and Group II patients. Sinus rhythm was preserved in all Group I patients when it was achieved during amiodarone administration. Limiting adverse effects occurred in 3 (11.1%) patients in Group I. In patients regaining sinus rhythm after the first episode of persistent AF, a 3-month amiodarone treatment after reversion is a reasonable option for rhythm control.